HDL Therapeutics Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Reverse Merger
- (Announced)
- Latest Deal Amount
-
$480M
HDL Therapeutics General Information
Description
Operator of a commercial-stage biotechnology company intended to fight heart disease. The company offers FDA (food and drug administration) approved therapies, enabling physicians to reduce coronary atheroma in a rare cardiovascular disease.
Contact Information
Website
www.hdltherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Primary Office
- 601 21st Street
- Suite 300
- Vero Beach, FL 32960
- United States
+1 (772) 000-0000
HDL Therapeutics Timeline
HDL Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Reverse Merger | 24-Apr-2023 | $480M | 000.00 | Announced | Generating Revenue | |
| 5. Later Stage VC | 11-Jul-2023 | 00.000 | 000.00 | Completed | Generating Revenue | |
| 4. Later Stage VC (Series E) | 04-Mar-2021 | 00.000 | 00.00 | Completed | Generating Revenue | |
| 3. Later Stage VC (Series D) | 03-Oct-2019 | 000 | 00.000 | Completed | Generating Revenue | |
| 2. Early Stage VC | 31-Dec-2014 | $2.04M | $2.97M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 13-Feb-2013 | $925K | $925K | 00.000 | Completed | Generating Revenue |
HDL Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00 | 00 | 00 | 00.000 |
HDL Therapeutics Patents
HDL Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210283201-A1 | Systems and methods for treating patients infected with sars-cov-2 | Pending | 06-Mar-2020 | 00000000 | 0 |
| AU-2019389048-A1 | Methods for treating lipid-related diseases including xanthomas, carotid artery stenoses, and cerebral atherosclerosis | Pending | 30-Nov-2018 | 00000000 | |
| CA-3121552-A1 | Methods for treating lipid-related diseases including xanthomas, carotid artery stenoses, and cerebral atherosclerosis | Pending | 30-Nov-2018 | 00000000 | |
| EP-3886871-A1 | Methods for treating lipid-related diseases including xanthomas, carotid artery stenoses, and cerebral atherosclerosis | Inactive | 30-Nov-2018 | 00000000 | |
| EP-3886871-A4 | Methods for treating lipid-related diseases including xanthomas, carotid artery stenoses, and cerebral atherosclerosis | Inactive | 30-Nov-2018 | A61P3/06 | 0 |
HDL Therapeutics Executive Team (5)
HDL Therapeutics Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bryan Brewer MD | HDL Therapeutics | Co-Founder, Chief Scientific Officer & Board Member | 000 0000 |
| Dane Andreeff | Self | Board Member | 000 0000 |
| Gregg Sessa | Self | Board Member | 000 0000 |
| Michael Matin | HDL Therapeutics | Co-Founder, Chief Executive Officer & Chairman | 000 0000 |
HDL Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
HDL Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Swiftmerge Acquisition | 11-Aug-2023 | 0000000000 | Special Purpose Acquisition Company (SPAC) |